# reload+after+2024-01-22 13:45:08.678708
address1§700 Park Offices Drive
address2§Suite 200
city§Research Triangle Park
state§NC
zip§27709
country§United States
phone§919 213 9835
fax§919 741 5830
website§https://www.g1therapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
fullTimeEmployees§170
companyOfficers§[{'maxAge': 1, 'name': 'Mr. John E. Bailey Jr.', 'age': 58, 'title': 'CEO, President & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 1060200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Avagliano', 'age': 47, 'title': 'Chief Business Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 628537, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John W. Umstead V', 'age': 38, 'title': 'Chief Financial Officer', 'yearBorn': 1985, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Terry L. Murdock', 'age': 63, 'title': 'Chief Operating Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 541585, 'exercisedValue': 606336, 'unexercisedValue': 88734}, {'maxAge': 1, 'name': 'Mr. William C. Roberts', 'age': 54, 'title': 'Vice President of Investor Relations & Corporate Communications', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Monica R. Thomas', 'title': 'General Counsel & Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Evan  Hicks M.B.A.', 'title': 'Vice President of Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rajesh K. Malik Ch.B., M.B., M.D.', 'age': 64, 'title': 'Chief Medical Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 596373, 'exercisedValue': 1477089, 'unexercisedValue': 1626553}, {'maxAge': 1, 'name': 'Mr. Andrew  Perry', 'age': 50, 'title': 'Chief Commercial Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 568603, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeff  Macdonald', 'title': 'Senior Director of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.726
priceToSalesTrailing12Months§1.9369501
currency§USD
dateShortInterest§1702598400
forwardEps§-0.91
exchange§NMS
quoteType§EQUITY
shortName§G1 Therapeutics, Inc.
longName§G1 Therapeutics, Inc.
firstTradeDateEpochUtc§1495027800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§bd84c3e0-0dae-33f1-b209-a61564837b23
gmtOffSetMilliseconds§-18000000
targetHighPrice§14.0
targetLowPrice§5.0
targetMeanPrice§9.0
targetMedianPrice§8.5
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§3.079
grossMargins§0.91100997
ebitdaMargins§-0.78265
trailingPegRatio§None
